NCT02066012

Brief Summary

Dysmetabolic iron overload syndrome (DIOS), is a frequent hepatic iron overload associated with metabolic syndrome. We hypothesize that this mild iron overload can induce a increased macrophagic polarization towards inflammatory types, thereby contributing to cardiovascular risk. Our main objective is to highlight the influence of iron overload on polarization capacity of monocytes into alternative macrophages (called M2). We therefore compare phenotypic markers of monocytes/macrophages between subjects with DIOS, metabolic syndrome without iron overload and lean subjects.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2014

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2014

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

February 14, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 19, 2014

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
Last Updated

February 19, 2014

Status Verified

February 1, 2014

Enrollment Period

6 months

First QC Date

February 14, 2014

Last Update Submit

February 17, 2014

Conditions

Keywords

Dysmetabolic Iron Overload SyndromeMetabolic Syndrome XIronMonocyteMacrophagePolarization

Outcome Measures

Primary Outcomes (1)

  • Expression (RNA) of macrophagic polarization markers

    Expression (RNA) of macrophagic polarization markers (MR, CD200R, F13A1, CD163, AMAC1, TGFβ), among subjects with or without iron overload

    at day 1

Secondary Outcomes (1)

  • characteristics of the subjects

    at day 1

Study Arms (3)

group DIOS

group DIOS composed of subjects with dysmetabolic hepatosiderosis

Other: dysmetabolic iron overload syndrome

group M

group M composed of subjects with metabolic syndrom without iron overload

Other: dysmetabolic iron overload syndrome

group T

group T composed of lean subjects

Other: dysmetabolic iron overload syndrome

Interventions

group DIOSgroup Mgroup T

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

metabolic syndrome

You may qualify if:

  • 18 years old and over
  • written consent
  • for groups M and HSD at least one criteria of the metabolic syndrome definition according to the International Diabetes Federation
  • for group M only hepatic iron overload mesured by IRM (above 50 µmol/g) hyperferritnemia between 450 and 1500 µg/l
  • for group T only BMI \< 25 kg/m² Waist size \< 80 cm for women and \<94 cm for men

You may not qualify if:

  • persons under guardianship
  • pregnancy
  • active smoking
  • current inflammatory or cancerous disease
  • hereditary hemochromatosis
  • use of anti-inflammatory, immunosuppressive or hypoglycaemic drugs
  • hemolysis
  • alcool consumption above 14 doses for women and 21 doses for men per week
  • history of therapeutic phlebotomy
  • inflammatory syndrome with CRP above 15 mg/l

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, 63003, France

RECRUITING

MeSH Terms

Conditions

Metabolic Syndrome

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Marc RUIVARD

    University Hospital, Clermont-Ferrand

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 14, 2014

First Posted

February 19, 2014

Study Start

February 1, 2014

Primary Completion

August 1, 2014

Study Completion

October 1, 2014

Last Updated

February 19, 2014

Record last verified: 2014-02

Locations